Writing Committee; Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK et al (2023) 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 81(11):1076–1126

Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK (2021) ATTR amyloidosis: current and emerging management strategies: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 3(4):488–505

Article  PubMed  PubMed Central  Google Scholar 

Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872–2891

Article  PubMed  PubMed Central  CAS  Google Scholar 

Merlini G (2023) A step forward in solving amyloidosis. N Engl J Med 389(17):1615–1617

Article  PubMed  Google Scholar 

Tschope C, Elsanhoury A. Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges. J Clin Med. 2022;11(8).

Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2024.

Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML et al (2021) CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 385(6):493–502

Article  PubMed  CAS  Google Scholar 

Almeida M, Ranisch R (2022) Beyond safety: mapping the ethical debate on heritable genome editing interventions. Humanities and Social Sciences Communications 9(1):139

Article  Google Scholar 

Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F et al (2023) Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 389(17):1553–1565

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hung RR, Correia Ed, Berk JL, Drachman B, Fontana M, Gillmore JD, et al. Abstract 13273: APOLLO-B, a study of patisiran in patients with transthyretin cardiac amyloidosis: primary long-term results from the open-label extension period. Circulation. 2023;148(Suppl_1):A13273-A.

Buxbaum JN, Reixach N (2009) Transthyretin: the servant of many masters. Cell Mol Life Sci 66(19):3095–3101

Article  PubMed  PubMed Central  CAS  Google Scholar 

Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I et al (2023) World Heart Federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM). Glob Heart 18(1):59

Article  PubMed  PubMed Central  Google Scholar 

Hund E, Linke RP, Willig F, Grau A (2001) Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment Neurology 56(4):431–435

PubMed  CAS  Google Scholar 

Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B et al (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68(2):161–172

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS et al (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in Black Americans. N Engl J Med 336(7):466–473

Article  PubMed  CAS  Google Scholar 

Iorio A, De Lillo A, De Angelis F, Di Girolamo M, Luigetti M, Sabatelli M et al (2017) Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis. Eur J Hum Genet 25(9):1055–1060

Article  PubMed  PubMed Central  CAS  Google Scholar 

Griffin JM, Rosenblum H, Maurer MS (2021) Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res 128(10):1554–1575

Article  PubMed  PubMed Central  CAS  Google Scholar 

Brannagan TH 3rd, Berk JL, Gillmore JD, Maurer MS, Waddington-Cruz M, Fontana M et al (2022) Liver-directed drugs for transthyretin-mediated amyloidosis. J Peripher Nerv Syst 27(4):228–237

Article  PubMed  PubMed Central  CAS  Google Scholar 

Viney NJ, Guo S, Tai LJ, Baker BF, Aghajan M, Jung SW et al (2021) Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail 8(1):652–661

Article  PubMed  Google Scholar 

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22–31

Article  PubMed  CAS  Google Scholar 

Gales L. Tegsedi (inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis. Pharmaceuticals (Basel). 2019;12(2).

24 month open label study of the tolerability and efficacy of inotersen in TTR amyloid cardiomyopathy patients: ClinicalTrials.gov; 2018 [updated 2018/10/12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03702829.

Akcea T. TEGSEDI REMS (risk evaluation and mitigation strategy) program - Tegsedi REMS 2025 [Available from: https://www.tegsedirems.com.

Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, Franca MC Jr et al (2023) Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 330(15):1448–1458

Article  PubMed  PubMed Central  CAS  Google Scholar 

Masri A, Maurer MS, Claggett BL, Kulac I, Waddington Cruz M, Conceicao I et al (2024) Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis. J Card Fail 30(8):973–980

Article  PubMed  Google Scholar 

Miller CM, Tanowitz M, Donner AJ, Prakash TP, Swayze EE, Harris EN et al (2018) Receptor-mediated uptake of phosphorothioate antisense oligonucleotides in different cell types of the liver. Nucleic Acid Ther 28(3):119–127

Article  PubMed  PubMed Central  CAS  Google Scholar 

Baker BF, Xia S, Partridge W, Kwoh TJ, Tsimikas S, Bhanot S et al (2023) Integrated assessment of phase 2 data on GalNAc(3)-conjugated 2’-O-methoxyethyl-modified antisense oligonucleotides. Nucleic Acid Ther 33(1):72–80

Article  PubMed  CAS  Google Scholar 

Debacker AJ, Voutila J, Catley M, Blakey D, Habib N (2020) Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther 28(8):1759–1771

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wada F, Yamamoto T, Ueda T, Sawamura M, Wada S, Harada-Shiba M et al (2018) Cholesterol-GalNAc dual conjugation strategy for reducing renal distribution of antisense oligonucleotides. Nucleic Acid Ther 28(1):50–57

Article  PubMed  CAS  Google Scholar 

Urits I, Swanson D, Swett MC, Patel A, Berardino K, Amgalan A et al (2020) A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther 9(2):301–315

Article  PubMed  PubMed Central  Google Scholar 

Dana H, Chalbatani GM, Mahmoodzadeh H, Karimloo R, Rezaiean O, Moradzadeh A et al (2017) Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci 13(2):48–57

Article  PubMed  PubMed Central  Google Scholar 

Chery J (2016) RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J 4(7):35–50

Article  PubMed  PubMed Central  Google Scholar 

Leung AK, Tam YY, Cullis PR (2014) Lipid nanoparticles for short interfering RNA delivery. Adv Genet 88:71–110

Article  PubMed  CAS  Google Scholar 

Springer AD, Dowdy SF (2018) GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther 28(3):109–118

Article  PubMed  PubMed Central  CAS  Google Scholar 

Judge DP, Kristen AV, Grogan M, Maurer MS, Falk RH, Hanna M et al (2020) Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther 34(3):357–370

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fontana M, Maurer Mathew S, Gillmore Julian D, Bender S, Aldinc E, Eraly Satish A, et al. Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial. Journal of the American College of Cardiology.0(0).